Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Advances in Experimental Medicine and Biology|November 12, 2025
Modulating the Allergen-Specific Immune Response to Achieve Remission of Food Allergy Through Oral ImmunotherapySarah E Ashley, Mimi L K TangMolecular and Cellular Endocrinology|July 14, 2012
AMPK and the neuroendocrine regulation of appetite and energy expenditureRomana Stark, Sarah E Ashley, Zane B AndrewsPediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|March 23, 2024
Transcriptomic changes associated with oral immunotherapy for food allergySarah E Ashley, Anthony Bosco, Mimi L K TangJournal of Visualized Experiments : Jove|July 10, 2018
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass SpectrometrySarah E Ashley, Braydon A Meyer, Justine A Ellis, et al.Allergy|May 26, 2022
Remission of peanut allergy is associated with rewiring of allergen-driven T helper 2-related gene networksSarah E Ashley, Anya C Jones, Denise Anderson, et al.Allergy|December 26, 2024
Allergen-Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1-10 YearsSarah E Ashley, Melanie Lloyd, Paxton Loke, et al.Allergy|July 22, 2025
Understanding the Variability of Peanut-Oral Immunotherapy Responses by Multi-Omics Profiling of Immune CellsAleix Arnau-Soler, Sarah E Ashley, Ahla Ghauri, et al.Allergy|August 5, 2024
Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) studyPaxton Loke, Xiaofang Wang, Melanie Lloyd, et al.The Lancet. Child & Adolescent Health|February 6, 2022
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trialPaxton Loke, Francesca Orsini, Adriana C Lozinsky, et al.Pageof 1